ENXTAM:GLPGBiotechs
Galapagos’ Cell Therapy Exit Amid Promising GLPG5101 Data Might Change The Case For Investing In Galapagos (ENXTAM:GLPG)
In early December 2025, Galapagos NV reported updated Phase 2 ATALANTA-1 data showing high complete response rates and durable outcomes for its CD19 CAR T-cell candidate GLPG5101 in high-risk mantle cell lymphoma, with rapid manufacturing timelines and limited severe toxicities.
On the same occasion, Galapagos confirmed plans to wind down its cell therapy activities, while remaining open to a potential sale, highlighting a contrast between promising clinical results and a retreat from...